Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jubilant Pharmova's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 42.95.
Jubilant Pharmova's Days Inventory for the
three
months ended in Mar. 2026 was 157.54.
Jubilant Pharmova's Days Payable for the
three
months ended in Mar. 2026 was 157.87.
Therefore, Jubilant Pharmova's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 42.62.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Jubilant Pharmova Cash Conversion Cycle Related Terms
Jubilant Pharmova Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Jubilant Pharmova's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530019 vs ZTS, UTHR: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jubilant Pharmova Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Jubilant Pharmova's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Jubilant Pharmova's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jubilant Pharmova (BOM:530019) has a Cash Conversion Cycle of 42.62 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Jubilant Pharmova and its competitors.
Is Jubilant Pharmova's Cash Conversion Cycle too high?
Jubilant Pharmova's current Cash Conversion Cycle is 42.62. The Drug Manufacturers industry median Cash Conversion Cycle is 145.92. Jubilant Pharmova's value of 42.62 is 70.8% below this industry median. Overall, Jubilant Pharmova has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jubilant Pharmova's Cash Conversion Cycle compare to ZTS and UTHR?
Jubilant Pharmova's Cash Conversion Cycle of 42.62 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.92. Jubilant Pharmova's value of 42.62 is 70.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.92, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jubilant Pharmova's current Cash Conversion Cycle of 42.62 is 70.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Jubilant Pharmova and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jubilant Pharmova's current Cash Conversion Cycle is 42.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jubilant Pharmova stock overvalued right now?
Based on GuruFocus' analysis, Jubilant Pharmova (BOM:530019) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,060.40, compared to a current price of ₹1,023.95 — trading 3.4% below its estimated fair value. The current Cash Conversion Cycle is 42.62 and 70.8% below the Drug Manufacturers industry median of 145.92. Jubilant Pharmova's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Jubilant Pharmova (BOM:530019), the current Cash Conversion Cycle is 42.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jubilant Pharmova (BOM:530019) Overvalued in 2026?
Based on GuruFocus' analysis, Jubilant Pharmova stock appears to be undervalued.
The current stock price of ₹1,023.95 is trading 3.4% below its estimated GF Value™ of ₹1,060.40.
GuruFocus considers Jubilant Pharmova to be Fairly Valued.
Key valuation signals for BOM:530019:
Cash Conversion Cycle: 42.62
GF Value™: ₹1,060.40 vs. price of ₹1,023.95 (3.4% below fair value)
Industry Position: 70.8% below the Drug Manufacturers median
No single metric tells the full story. See the BOM:530019 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
69GF Score
Get the complete analysis for BOM:530019
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530019 has been successfully added to your 
